



5.90.037

Section:	Prescription Drugs	Effective Date:	October 1, 2024
Subsection:	Topical Products	Original Policy Date:	November 8, 2018
Subject:	Qbrexza	Page:	1 of 4

Last Review Date: September 6, 2024

Qbrexza

Description

Qbrexza (glycopyrronium)

Background

Qbrexza (glycopyrronium) is a competitive inhibitor of acetylcholine receptors that are located on certain peripheral tissues, including sweat glands. In hyperhidrosis, Qbrexza inhibits the action of acetylcholine on sweat glands, which reduces sweating (1).

Regulatory Status

FDA-approved indication: Qbrexza is an anticholinergic indicated for topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older (1).

Qbrexza should be used with caution in patients with a history or presence of documented urinary retention. Prescribers and patients should be alert for signs and symptoms of urinary retention (e.g., difficulty passing urine, distended bladder), especially in patients with prostatic hypertrophy or bladder-neck obstruction. Patients should be instructed to discontinue use immediately and consult a physician should any of these signs or symptoms develop (1).

In the presence of high ambient temperature, heat illness (hyperpyrexia and heat stroke due to decreased sweating) can occur with the use of anticholinergic drugs such as Qbrexza. Patients using Qbrexza should be advised to watch for generalized lack of sweating when in hot or very warm environmental temperatures and to avoid use if not sweating under these conditions (1).

Transient blurred vision may occur with use of Qbrexza. If blurred vision occurs, the patient should discontinue use until symptoms resolve. Patients should be warned not to engage in

Section:	Prescription Drugs	Effective Date:	October 1, 2024
Subsection:	Topical Products	Original Policy Date:	November 30, 2018
Subject:	Qbrexza	Page:	2 of 4

activities that require clear vision such as operating a motor vehicle or other machinery or performing hazardous work until the symptoms have resolved (1).

The safety and efficacy of Qbrexza have not been established in pediatric patients under 9 years of age (1).

Related policies

Policy

This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.

Qbrexza may be considered **medically necessary** if the conditions indicated below are met.

Qbrexza may be considered **investigational** for all other indications.

Prior-Approval Requirements

Age 9 years of age and older

Diagnosis

Patient must have the following:

Primary axillary hyperhidrosis

AND ALL of the following:

1. Inadequate treatment response, intolerance, or contraindication to **ALL** of the following:
 - a. **ONE** over the counter topical antiperspirant (e.g., Bromi-lotion)
 - b. **ONE** legend aluminum chloride-containing topical antiperspirants (e.g., Drysol, Hypercare, Xerac AC)
2. Documented baseline evaluation of the condition using a scoring tool, such as the Hyperhidrosis Disease Severity Scale (HDSS) (e.g., <https://www.sweathelp.org/pdf/HDSS.pdf>)

AND NONE of the following:

1. Glaucoma
2. Paralytic ileus

Section:	Prescription Drugs	Effective Date:	October 1, 2024
Subsection:	Topical Products	Original Policy Date:	November 30, 2018
Subject:	Qbrexza	Page:	3 of 4

3. Unstable cardiovascular status in acute hemorrhage
4. Severe ulcerative colitis
5. Toxic megacolon complicating ulcerative colitis
6. Myasthenia gravis
7. Sjogren's syndrome

Prior – Approval *Renewal* Requirements

Age 9 years of age and older

Diagnosis

Patient must have the following:

Primary axillary hyperhidrosis

AND the following:

1. Documented improvement from baseline using a scoring tool such as the Hyperhidrosis Disease Severity Scale (HDSS) (e.g., <https://www.sweathelp.org/pdf/HDSS.pdf>)

AND NONE of the following:

1. Glaucoma
2. Paralytic ileus
3. Unstable cardiovascular status in acute hemorrhage
4. Severe ulcerative colitis
5. Toxic megacolon complicating ulcerative colitis
6. Myasthenia gravis
7. Sjogren's syndrome

Policy Guidelines

Pre - PA Allowance

None

Prior - Approval Limits

Quantity 90 cloths per 90 days

Duration 12 months

Section:	Prescription Drugs	Effective Date:	October 1, 2024
Subsection:	Topical Products	Original Policy Date:	November 30, 2018
Subject:	Qbrexza	Page:	4 of 4

Prior – Approval *Renewal* Limits

Same as above

Rationale

Summary

Qbrexza (glycopyrronium) is a competitive inhibitor of acetylcholine receptors that are located on certain peripheral tissues, including sweat glands. In hyperhidrosis, Qbrexza inhibits the action of acetylcholine on sweat glands, which reduces sweating. The safety and efficacy of Qbrexza have not established in pediatric patients under 9 years of age (1).

Prior authorization is required to ensure the safe, clinically appropriate, and cost-effective use of Qbrexza while maintaining optimal therapeutic outcomes.

References

1. Qbrexza [package insert]. Scottsdale, AZ: Journey Medical Corporation; November 2022.

Policy History

Date	Action
May 2019	New addition
June 2019	Annual review. Revised continuation criteria to include documented improvement in symptoms
September 2020	Annual review
September 2021	Annual review and reference update. Per MQA, added requirements: patient needs to have a documented baseline score such as HDSS and improvement in score for renewal. Per MQA, revised initiation requirement from t/f of two OTC antiperspirants to t/f one OTC and one legend aluminum chloride-containing topical antiperspirants
September 2022	Annual review
September 2023	Annual review and reference update
September 2024	Annual review

Keywords

5.90.037

Section: Prescription Drugs

Effective Date: October 1, 2024

Subsection: Topical Products

Original Policy Date: November 30, 2018

Subject: Qbrexza

Page: 5 of 4

This policy was approved by the FEP® Pharmacy and Medical Policy Committee on September 6, 2024 and is effective on October 1, 2024.